mosunetuzumab
roche
['mosunetuzumab', 'lymsm']
 presenting updated phase ii data on mosunetuzumab in fl - focus on pts who achieved cr with durable response, with similar dor independent of time to cr, no association with mtv, and higher crs risk with marrow involvement #17icml #lymsm 
Heme/Onc fellow @UCCancerCenter interested in aggressive lymphoma, novel therapeutics, and cellular therapies #lymsm #TcellRx. Views are my own.